Evidence map›Paper›PMID 38273779›Full record

ArticlePediatric dermatology

Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning-Feuerstein-Mims syndrome.

Courtney N Haller, Maria A Leszczynska, Lars Brichta, Esther Maier, Ian M Riddington, Keith A Choate, Moise L Levy

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Courtney N HallerDepartment of Internal Medicine, Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas, USA.
Maria A LeszczynskaDepartment of Dermatology, Baylor Scott and White, Temple, Texas, USA.ORCID https://orcid.org/0000-0002-4965-0050
Lars BrichtaChemistry Rx Compounding and Specialty Pharmacy, Folcroft, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-9103-609X
Esther MaierDrug Dynamics Institute, College of Pharmacy, The University of Texas, Austin, Texas, USA.
Ian M RiddingtonDepartment of Chemistry, The University of Texas, Austin, Texas, USA.
Keith A ChoateDepartment of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Moise L LevyDepartment of Internal Medicine, Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas, USA.
The University of Texas at Austin · USAustin College · USBaylor Scott & White Medical Center - Temple · USDell Children's Medical Center of Central Texas · USYale University · US

Funding

Genetics and Pathobiology of Cutaneous Mosaic DisordersR01AR071491 · NIAMS · YALE UNIVERSITY · PI KEITH A CHOATE · 2018 to 2026
$4.2M
NIAMS NIH HHS R01 AR071491NIH/NIAMS R01AR071491
6 · The paper itself

Abstract

We present the case of a 20-month-old girl with Schimmelpenning-Feuerstein-Mims (SFM) syndrome with extensive head, neck, and torso skin involvement successfully managed with topical trametinib. Trametinib interferes downstream of KRAS and HRAS in the MAPK signaling pathway, of which KRAS was implicated in our child's pathogenic variant. Although other dermatologic conditions have shown benefit from oral trametinib, its topical use has not been well reported. Our patient showed benefit from the use of twice-daily topical trametinib, applied to the epidermal and sebaceous nevi over a 16-month period, leading to decreased pruritus and thinning of the plaques.

Indexed as

PyridonesPyrimidinonesSkin NeoplasmsAbnormalities, MultipleAdministration, TopicalAntineoplastic AgentsEye AbnormalitiesFailure to ThriveFemaleHumansInfantNeurocutaneous SyndromesNevusNevus, Sebaceous of JadassohnPrimary Immunodeficiency DiseasesSkin AbnormalitiesAntineoplastic AgentsPyridonesPyrimidinonesadministrationdermatologynevuspediatricspharmaceutical preparationsSchimmelpenning‐Feuerstein‐Mims syndromesebaceous of Jadassohnskin creamtherapeuticstopicaltrametinib

Identifiers

PMID38273779
PMCPMC11096062
OpenAlexW4391259900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.